The increased mortality observed in the intensive glycemic control arm in the ACCORD trial is not likely to be explained by QT prolongation leading to lethal ventricular arrhythmias (Diabetes)
Diabetes News
Tag: BP
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes
Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Although BP reduction associated to empagliflozin therapy may partly contribute to the benefits reported in EMPA-REG OUTCOME, other mechanisms most probably play a greater role in the overall CV protection and reduction in mortality observed in this trial (Diabetes Research and Clinical Practice)
Glycosmedia is also available as an App: